digitoxin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
881 71-63-6

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • digitoxin
  • digitoxoside
  • cardidigin
  • cardigin
  • carditoxin
  • coramedan
  • cristapurat
  • crystodigin
  • digicor
  • digipural
  • digisidin
  • digitophyllin
  • digitoxigenin tridigitoxoside
  • myodigin
  • purpurid
  • tradigal
  • unidigin
A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665)
  • Molecular weight: 764.95
  • Formula: C41H64O13
  • CLOGP: 2.85
  • LIPINSKI: 2
  • HAC: 13
  • HDO: 5
  • TPSA: 182.83
  • ALOGS: -4.42
  • ROTB: 7

  • Status: OFM

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.10 mg O
0.10 mg P

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 3 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.01 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 30 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.00 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.44 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 0.04 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.07 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 180 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
None FDA LILLY

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Bradycardia 149.03 29.45 82 3634 66216 46616130
General physical health deterioration 141.59 29.45 97 3619 115672 46566674
Product prescribing error 131.11 29.45 52 3664 19995 46662351
Arrhythmia 130.78 29.45 61 3655 34780 46647566
Atrial fibrillation 127.08 29.45 87 3629 103503 46578843
Wound 77.38 29.45 46 3670 42756 46639590
Product monitoring error 77.07 29.45 20 3696 1961 46680385
Therapeutic drug monitoring analysis not performed 74.35 29.45 15 3701 475 46681871
Cardiac failure 59.69 29.45 50 3666 79898 46602448
Fall 59.55 29.45 99 3617 328998 46353348
Anaemia 57.40 29.45 85 3631 255694 46426652
Tachycardia 53.99 29.45 52 3664 99570 46582776
Cerebrospinal fluid retention 47.99 29.45 8 3708 84 46682262
Syncope 44.55 29.45 48 3668 104755 46577591
Bradyarrhythmia 44.38 29.45 13 3703 1993 46680353
Fracture 44.26 29.45 23 3693 16448 46665898
Drug interaction 43.35 29.45 66 3650 203028 46479318
Therapeutic drug monitoring analysis incorrectly performed 43.22 29.45 8 3708 159 46682187
Cerebral ventricular rupture 41.82 29.45 8 3708 191 46682155
Dyspnoea 39.15 29.45 109 3607 515439 46166907
Gastric pH increased 38.04 29.45 6 3710 43 46682303
Acute kidney injury 37.33 29.45 67 3649 235788 46446558
Cerebellar infarction 36.60 29.45 11 3705 1841 46680505
Dizziness 36.31 29.45 82 3634 340332 46342014
Platelet disorder 34.01 29.45 10 3706 1553 46680793
Reflexes abnormal 33.01 29.45 8 3708 593 46681753
Atrial flutter 31.14 29.45 15 3701 9133 46673213
Drug ineffective 30.97 29.45 8 3708 677830 46004516
Rhonchi 30.57 29.45 10 3706 2205 46680141

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
General physical health deterioration 156.02 28.79 107 2957 99837 29849577
Product prescribing error 88.01 28.79 40 3024 16693 29932721
Cardiac failure 86.47 28.79 70 2994 83348 29866066
Haematochezia 66.10 28.79 42 3022 34180 29915234
Dyspnoea 61.25 28.79 116 2948 333179 29616235
Product monitoring error 51.72 28.79 15 3049 1726 29947688
Therapeutic drug monitoring analysis not performed 50.46 28.79 11 3053 394 29949020
Oedema peripheral 40.71 28.79 52 3012 105780 29843634
Thoracic haemorrhage 39.13 28.79 8 3056 209 29949205
Bradyarrhythmia 37.37 28.79 12 3052 1940 29947474
Albumin urine present 34.46 28.79 8 3056 382 29949032
Spontaneous haemorrhage 33.91 28.79 7 3057 192 29949222
Wound 33.74 28.79 19 3045 12383 29937031
Post procedural haemorrhage 32.60 28.79 16 3048 7894 29941520
Mouth swelling 31.31 28.79 10 3054 1589 29947825
Gout 30.31 28.79 20 3044 17295 29932119

Pharmacologic Action:

SourceCodeDescription
ATC C01AA04 CARDIOVASCULAR SYSTEM
CARDIAC THERAPY
CARDIAC GLYCOSIDES
Digitalis glycosides
MeSH PA D000889 Anti-Arrhythmia Agents
MeSH PA D002316 Cardiotonic Agents
MeSH PA D002317 Cardiovascular Agents
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:63510 na(+)/k(+)-pump inhibitors

Drug Use (View source of the data)

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Sodium/potassium-transporting ATPase subunit alpha-1 Transporter INHIBITOR WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily H member 2 Ion channel IC50 4.86 WOMBAT-PK
Sodium/potassium-transporting ATPase Transporter IC50 8.10 CHEMBL
Signal transducer and activator of transcription 3 Transcription factor IC50 6.15 CHEMBL
Sodium/potassium-transporting ATPase subunit alpha-2 Ion channel IC50 6.65 DRUG MATRIX
Sodium/potassium-transporting ATPase subunit alpha-1 Transporter IC50 8.10 CHEMBL

External reference:

IDSource
4017429 VUID
N0000145817 NUI
D00297 KEGG_DRUG
4017429 VANDF
C0012258 UMLSCUI
CHEBI:28544 CHEBI
F9R PDB_CHEM_ID
CHEMBL254219 ChEMBL_ID
DB01396 DRUGBANK_ID
D004074 MESH_DESCRIPTOR_UI
3061 PUBCHEM_CID
6782 IUPHAR_LIGAND_ID
1547 INN_ID
E90NZP2L9U UNII
216288 RXNORM
195 MMSL
4596 MMSL
d00209 MMSL
000592 NDDF
373534001 SNOMEDCT_US
81728006 SNOMEDCT_US

Pharmaceutical products:

None